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Abstract
Introduction We sought to determine whether the levels of
expression of 17 candidate genes were associated with
locoregional control after breast-conserving treatments of early-
stage breast cancers in young, premenopausal women.
Methods Gene expression was measured by using RT-PCR in
the breast tumors of a series of 53 young (younger than 40
years), premenopausal patients. All treatments consisted of
primary breast-conserving surgery followed by whole-breast
radiotherapy (± regional lymph nodes) with or without systemic
treatments (chemotherapy ± hormone therapy). The median
follow-up was 10 years.
Results The 10-year locoregional control rate was 70% (95%
CI, 57% to 87%). In univariate analysis, no clinical/pathologic
prognostic factors were found to be significantly associated
with decreased locoregional control. Expression of three genes
was found to be significantly associated with an increased
locoregional recurrence rate: low estrogen-receptor  β, low
aromatase, and high GATA3. Two others were associated with
only a trend (P < 0.10): low HER1 and SKP2. In multivariate
analysis, only the absence of aromatase was significantly
associated with an increased locoregional recurrence rate (P =
0.003; relative risk = 0.49; 95% CI 0.29 to 0.82).
Conclusions Recent data give credit to the fact that breast
cancer in young women is a distinct biologic entity driven by
special oncogenic pathways. Our results highlight the role of
estrogen-signaling pathways (mainly CYP19/aromatase,
GATA3, and ER-β) in the risk of locoregional recurrence of
breast cancer in young women. Confirmation in larger
prospective studies is needed.
Introduction
Breast-conserving therapy is the preferred treatment for
patients with early-stage breast cancer [1]. It offers equal local
control and overall survival [2], as well as superior psychoso-
cial outcomes compared with modified radical mastectomy
[3,4]. Locoregional recurrences can be traumatizing and even
CAF-1: chromatin assembly factor 1; CCNE1: cyclin E1; CCNE1: cyclin E2; CI: confidence interval; CYP19: aromatase; EORTC: European Organ-
isation for Research and Treatment of Cancer; ER: estrogen receptor; GATA3: GATA-binding protein 3; Gy: Gray; HER: human epidermal receptor; 
HR: hormone receptor; IGF1R: insulin-like growth factor 1-receptor; MKI67: antigen identified by monoclonal antibody ki-67; NCoA3/AIB1: nuclear 
receptor co-activator 3; NCoR: nuclear receptor co-repressor; PR: progesterone receptor; Pts: patients; RR: relative risk; RT-PCR: reverse tran-
scriptase polymerase chain reaction; SKP2: S-phase kinase-associated protein 2; TBP: TATA box-binding protein.Breast Cancer Research    Vol 11 No 4    Bollet et al.
Page 2 of 11
(page number not for citation purposes)
fatal, despite aggressive therapies [2]. Young age is generally
considered to be the most important risk factor for locore-
gional recurrence after breast-conserving treatments [5-7].
This higher risk, which is not yet understood despite numerous
studies, could find its explanation in tumor biology.
The hormonal environment, with menopause as its archetype
epitome, is the major physiological difference between
younger and older patients. Estrogens not only are the main
regulators of growth and differentiation in the normal mammary
gland, but also play a major role in the onset and progression
of breast cancer [8,9] (reviewed by Yager [10]). Other signal-
ing pathways, not directly related to estrogen receptors (ERs),
also are involved in the growth of epithelial tissues.
In premenopausal breast cancer patients, little is known about
the expression levels of genes that are directly or indirectly
involved in hormone (especially ER) and growth factors signal-
ing pathways. The aim of this study, conducted in a series of
women diagnosed with invasive breast cancers before the age
of 40, was therefore to determine the relation between locore-
gional relapse, classic biopathologic factors, and the intratu-
moral levels of gene expression of 17 hormone receptors,
growth-factor receptors, or proliferation genes: ERα,  ERβ,
progesterone receptor (PR),  nuclear receptor co-repressor
(NCoR), nuclear receptor coactivator 3 (NCoA3/AIB1), aro-
matase (CYP19), GATA-binding protein 3 (GATA3), human
epidermal receptor (HER) 1 to 4, insulin-like growth factor 1-
receptor (IGF1R), antigen identified by monoclonal antibody
ki-67 (MKI67), cyclin E1 (CCNE1), cyclin E2 (CCNE1), S-
phase kinase-associated protein 2 (SKP2), and the two sub-
units of chromatin assembly factor 1 (CAF-1 p150 and CAF-
1 p60). Quantitative reverse-transcriptase polymerase chain
reaction (RT-PCR) was chosen, as it is the most precise
method to measure absolute levels of expression of selected
target genes within a wide range, from very high to very low
transcript levels [11,12].
Materials and methods
1.1 Patients and tissue specimens
Between 1988 and 1999, 257 premenopausal women,
younger than 40 years, with no previous history of cancer were
treated at the Institut Curie for early unilateral breast cancers.
The present retrospective study was based on 53 of these
257 patients for whom frozen tumor tissue was available.
Median age at diagnosis was 37 years (range, 23 to 40) with
30% of patients (16 patients) no older than 36 years. Median
follow-up was 10 years (range, 2 to 18 years).
Patient and tumor characteristics are reported in Table 1. Clin-
ical stage [13] was either T1 or T2, N0 or N1. All specimens
were reviewed by the same pathologist (BSZ). Histologic clas-
sification of the infiltrating carcinomas was reported according
to the World Health Organization criteria, and histologic grade
was reported according to Ellis and Elston [14]. The median
number of mitoses, calculated per 10 high-power fields [15],
was 13 (2 to 120). Hormone receptors (HRs) were positive
when nuclear staining for either estradiol receptors (ERs) or
progesterone receptors (PRs) was observed in at least 10%
of invasive cells with immunohistochemistry [16]. No patho-
logic axillary lymph node involvement was observed in 31
(58%) patients.
This study was approved by the Institutional Review Board and
Ethics committee. Patients were informed that their biologic
samples could be used for research purposes and that they
had the right to refuse if they so wished.
1.2 Treatments
Surgery consisted of breast-conserving procedures as first-
line treatment in all cases. The quality of the surgical margins
was classified as wide (more than 3 mm) in 32 (65%) patients,
close (3 mm or less) in 11 (22%) patients, involved with ductal
carcinoma in situ in 2 (4%) patients, involved with invasive car-
cinoma in 4 (8%) patients, and unknown in 4 patients. Axillary
lymph node dissection was performed in all patients.
Patients received posttumorectomy radiotherapy with a
median dose of 51 Gy (range, 45 to 54 Gy) to the breast. A
boost to the tumor bed was performed for 40 (75%) of
patients with a median dose of 16 Gy (range, 7 to 25 Gy). The
median total dose to the tumor bed was 66 Gy (range, 50 to
75 Gy). Supraclavicular irradiation was performed in 27 (51%)
of patients. Internal mammary irradiation was performed in 38
(72%) of patients. In the case of lymph node involvement, the
internal mammary chain and the supraclavicular area were
both irradiated. In the absence of lymph node involvement, irra-
diation of the internal mammary chain, with or without the supr-
aclavicular area, was indicated for centrally located tumors
with histopathologic features of aggressiveness. Axillary irradi-
ation was added in the presence of extensive axillary involve-
ment or in the absence of axillary lymph node dissection.
No protocol to boost all young patients with negative surgical
margins was available at that time, and some patients reported
in this series were accrued in the EORTC boost trial that ran-
domized between boost and no boost from 1989 to 1996
[5,17,18]. In the case of positive surgical margins, a radiother-
apy boost of generally 20 to 28 Gy was added to the whole-
breast irradiation. For patients not participating in the EORTC
randomized trial, a boost of 10 to 16 Gy was added in the case
of aggressive histopathologic features (unsatisfactory mar-
gins, high histopathologic grade, high proliferation index,
absence of hormone receptors).
The reasons for absence of repeated excision were not always
specified, but when they were specified, the reasons were the
patient's choice not to undergo a new surgical procedure that
could have been mastectomy.Available online http://breast-cancer-research.com/content/11/4/R54
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Table 1
Patient characteristics
RT-PCR series Whole series
Total n % n % P
Family history of breast cancer (MD = 0 and 1)a 0.77
Without 42 79 198 77
With 11 21 58 23
Age (MD = 0 and 0)a
Median (min-max) in years 37 (23–40) 37 (23–40) 0.71
≤ 35 years old 37 70 176 68 0.85
>  3 5  y e a r s  o l d 1 63 0 8 13 2
Clinical T stage (MD = 0 and 0)a 0.0496
cT0–1 31 58 186 72
c T 2 2 24 2 7 12 8
Clinical N stage (MD = 0 and 0)a 0.70
N0 52 98 246 96
N1 1 2 11 4
Type of invasive carcinoma (MD = 0 and 0)a 0.18b
Ductal 46 87 223 87
Lobular 6 11 16 6
Other 1 2 18 7
Histologic grade (MD = 0 and 1)a 0.03b
1–2 14 26 110 43
33 6 6 8 1 2 0 4 7
Unclassifiable 3 6 26 10
Estrogen receptor (ER) (MD = 6 and 37)a 0.59
ER- 10 21 55 25
ER+ 37 79 165 75
Progesterone receptor (PR) (MD = 6 and 39)a 0.84
PR- 91 9 3 9 1 8
PR+ 38 81 179 82
Hormone receptors (HRs) (MD = 6 and 37)a 0.87
HR- 71 5 3 5 1 6
HR+ 40 85 185 84
Lymphovascular involvement (MD = 3 and 43)a 0.0004
Absent 33 66 188 88
Present 17 34 26 12
Histologic T stage (MD = 5 and 12)a 0.89
pT1 34 71 176 72
p T 2 1 42 9 6 92 8Breast Cancer Research    Vol 11 No 4    Bollet et al.
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No systemic therapy was administered in 16 (30%) patients.
Chemotherapy only was given to 23 (43%) patients, consist-
ing of anthracycline-based combination chemotherapy in most
cases (usually six cycles of 5-fluorouracil, doxorubicin, and
cyclophosphamide). A combination of chemotherapy and hor-
mone therapy (tamoxifen for 5 years) was administered to 14
(26%) patients.
1.3 RNA isolation, RT-PCR
Total RNA was extracted from frozen tumor samples and first-
strand cDNA synthesis was performed, as previously
described from 1 μg of total RNA by using Superscript II RT
(Invitrogen, Carlsbad, CA, USA) [19]. ERα, ERβ, PR, HER1 to
HER4, MKi67, Cyclin E1 and E2, GATA3, IGF1-R, NCor,
NCoA3, CYP19 (aromatase gene), SKP2 and CAF-1 p150,
and CAF-1 p60 transcripts were quantified by using real-time
quantitative reverse transcription-PCR assays. The nucleotide
and probe sequences and the conditions of PCR were
described previously for ERα, ERβ, PR, HER1 to HER4,
MKi67, cyclin E1 and E2, NCor, NCoA3, CYP19 [see Addi-
tional data file 1] [19,20]. GATA3, IGF1R were quantified by
Assays-on-Demand from Applied Biosystems (Applied Bio-
systems, Inc., Foster City, CA). The nucleotide and probe
sequences SKP2 and CAF-1 were chosen with the help of
Primer express software (Applied Biosystems). TBP (TATA
box binding protein) was used as the endogenous reference
gene for immediate quantification of transcripts. Searches
were conducted in dbEST, htgs, and nr data bases [21] to
confirm the total gene specificity of nucleotide sequences.
Primers were placed at the junction between two exons. All
PCRs were performed in duplicate by using ABI Prism 7700
Sequence Detection System (Perkin Elmer Applied Biosys-
tems) and the Core reagent kit (Eurogentec). A 5-μl diluted
sample of cDNA (12.5 ng) was added to 20 μl of the PCR mix.
The thermal-cycling conditions comprised an initial denatura-
tion step at 95°C for 10 min, and 45 cycles at 95°C for 15 s
and either 60°C or 65°C, depending on the target, for 1 min.
Results were expressed as N-fold differences in target gene
expression relative to a reference gene defined as "N target"
(arbitrary units) and was determined as follows:
where E is the efficiency of PCR measured by using the slope
of the calibration curve, and Ct is the cycle threshold.
1.4 Statistical analysis
Survival rates, defined from the date of surgery to the occur-
rence of the event, were estimated by using the Kaplan-Meier
estimate; groups were compared by using the log-rank test.
Event-free patients were censored at the date of their last
known contact or death. Local relapses were defined as the
occurrence of breast carcinoma (either invasive or ductal car-
cinoma in situ) in the treated breast. Locoregional relapses
were our primary end point and were defined as either a local
relapse or a recurrence in the ipsilateral lymph node areas
(axillary, internal mammary, supraclavicular). Contralateral
N  t arget E E t arget
Ct   cal i br at or C t   sam pl e
r ef er ence  gene
C =
− () /
t t   cal i br at or C t   sam pl e − ()
Histologic N stage (MD = 0 and 34)a 0.06
pN0 31 58 182 73
pN1–3 22 42 41 27
Surgical margins (MD = 4 and 10)a 0.10
Satisfactory (≥ 3 mm) 32 65 129 52
Unsatisfactory 17 35 118 48
Systemic therapy (MD = 0 and 0)a 0.0001
None 16 30 151 59
Hormone therapy (HT) only 0 0 101 39
Chemotherapy ± HT 37 70 5 2
Total RT dose (MD = 0)a
Median (min-max) in Gy 66 (50–75) 64 (0–80) 0.14
< 60 Gy 13 25 101 39 0.043
≥ 60 Gy 40 75 156 61
Characteristics of the rt-PCR series (53 patients) in comparison to the whole population of consecutive patients with the same selection criteria 
treated over the same period (1988–1999) at the Institut Curie (257 patients). MD = missing data (both in the rt-PCR and in the whole series); 
total RT dose = total radiotherapy dose to the tumor bed (whole-breast radiotherapy dose + boost dose). a0.37 when the comparison excluded 
histologic types other than ductal or lobular. b0.05 when the comparison included all histologic grades.
Table 1 (Continued)
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breast cancers could be either ductal in situ or infiltrating car-
cinoma. Distant disease was defined as disease occurring
elsewhere than in the contralateral breast or locoregional site.
Disease-free was defined as the absence of locoregional or
distant relapses or both. Survival rates and relative risks (RRs)
are presented with their 95% confidence intervals (CIs).
Annual risks were calculated and plotted. The RT-PCR series
of 53 patients was compared with the whole series of all con-
secutive patients treated over the same period (1988 through
1999) at the Institut Curie (257 patients) after exclusion of the
RT-PCR patients. All gene expressions were analyzed as con-
tinuous variables to avoid having to search for cut-off values.
Fisher's Exact or χ2 tests were used to compare percentages,
as appropriate. Univariate analyses were performed to identify
prognostic factors of outcome and to estimate crude relative
risks (RRs). The influence of each factor, adjusted to the oth-
ers, was assessed in a multivariate analysis by the Cox propor-
tional hazards model [22]. A stepwise modeling algorithm was
used, with a limit of significance of 0.10 for entering and 0.05
for removing risk factors. The limit of significance was 0.05.
Analyses were performed by using R software, 2.5.0.
Results
The comparison of our series of patients with unselected, con-
secutive patients is summarized in Table 1. The patients ana-
lyzed with RT-PCR had tumors of higher clinical stage, higher
histologic grade, and more lymphovascular invasion, and more
often received chemotherapy and a total dose to the tumor
bed higher than 60 Gy. All other patient, tumor, and treatment
characteristics were similar.
Fifteen locoregional recurrences occurred (13 only local, 2
local and regional). Five-year and 10-year locoregional control
rates were 82% (95% CI, 72% to 93%) and 70% (95% CI,
57% to 87%), respectively. All local recurrences occurred in
the same quadrant as the primary tumor. Treatment of the local
recurrence included salvage mastectomy with or without sys-
temic therapy in 11 (73%) patients. In three (6%) patients,
contralateral breast cancer developed. In 15 patients, distant
metastases developed. Five-year and 10-year distant disease-
free survival rates were 82% (95% CI, 72% to 93%) and 69%
(95% CI, 56% to 85%), respectively. Five-year and 10-year
overall survival rates were 85% (95% CI, 76% to 95%) and
78% (95% CI, 65% to 92%), respectively. In no patient did a
second non-breast cancer develop.
Because regional recurrence was always accompanied by
local recurrence, risk factors for local and locoregional recur-
rence were the same (data not shown). In univariate analysis,
no clinicopathologic prognostic factor was found to be signif-
icantly associated with decreased locoregional control (Table
2). In univariate analysis, three gene-expression levels were
found to be significantly associated with an increased locore-
gional recurrence rate: low ERβ, low aromatase, high GATA3
(Table 3). Two other factors were associated only with a trend
(P < 0.10): low HER1 and SKP2. Multivariate analysis was
performed, taking the factors associated (P < 0.10) with loco-
regional recurrence into account in a Cox model (that is, 5 RT-
PCR features (ERβ, HER1, GATA3, SKP2 and aromatase).
Only low tumor expression of aromatase was significantly
associated with an increased locoregional recurrence rate (P
= 0.003; relative risk = 0.49; 95% CI, 0.29 to 0.82). Locore-
gional-free recurrence interval according to the level of intratu-
moral expression of aromatase with a cut-off at 5 is displayed
in Figure 1. GATA-3 was associated with a trend toward an
increased locoregional recurrence rate (P = 0.06; relative risk
= 1.49; 95% CI, 0.02 to 2.39).
Associations between gene expressions and locoregional
recurrences were looked for in two publicly available microar-
ray studies by Kreike and colleagues [23] and Nuyten and
associates [24] that gave information regarding the age of the
young women (48 and 35 patients with 18 and 7 local recur-
rences, respectively) treated with breast-conserving treat-
ments with whole-breast radiotherapy. They both failed to
show an association between the gene expression of either
aromatase or gata3 and local recurrences [see Additional data
file 2].
Discussion
This study was based on a series of 53 premenopausal
women younger than 40 years with a long (10 years) follow-up
treated at the Institut Curie for invasive breast cancer with pri-
mary breast-conserving surgery. Given the specificity of the
hormonal environment in young patients, genes directly or indi-
rectly involved in hormone and growth-factor signaling path-
ways were analyzed. In addition to the usual clinical and
histopathologic features, the levels of expression of 17 candi-
date genes for an association with locoregional control also
were examined.
Figure 1
Locoregional-free recurrence interval according to the level of intratu- moral expression of aromatase Locoregional-free recurrence interval according to the level of intratu-
moral expression of aromatase.Breast Cancer Research    Vol 11 No 4    Bollet et al.
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Table 2
Univariate analysis of clinical and histopathologic prognostic factors for locoregional control
rt-PCR series
n 10-year LRC (%)
[95% CI]
Pa RR [95% CI]
Family history of breast cancer 1.0
No 42 70 [56–87] 1
Yes 11 NA 1 [0.22–4.59]
Age (continuous variable) 0.38 0.94 [0.83–1.07]
Age (years; dummy variable) 0.57
> 35 16 73 [59–90] 1
≤ 35 37 60 [32–100] 1.37 [0.47–4.0]
Clinical tumor stage 0.71
cT1 31 70 [53–91] 1
cT2 22 74 [56–96] 0.81 [0.28–2.39]
Histologic T stage 0.55
pT1 34 70 [54–91] 1
pT2 14 70 [49–100] 0.71 [0.24–2.13]
Surgical margin 0.70
≥ 3 mm 32 61 [43–86] 1
< 3 mm 17 81 [64–100] 0.81 [0.27–2.37]
Lymphovascular invasion 0.78
Absent 33 71 [56–91] 1
Present 17 71 [50–100] 1.18 [0.36–3.87]
Histologic N stage 0.54
pN0 31 63 [47–84] 1
pN1 16 78 [53–100] 0.49 [0.13–1.77]
pN2 6 80 [52–100] 0.77 [0.17–3.52]
Histologic type 0.14
Ductal 46 75 [63–90] 1
Lobular 6 33 [7–100] 2.61 [0.72–9.53]
Estrogen receptors (ERs) 0.14
ER- 10 90 [73–100] 1
ER+ 37 63 [47–85] 4.28 [0.55–33.27]
Progesterone receptors (PR) 0.84
PR- 9 71 [43–100] 1
PR+ 38 69 [53–88] 1.18 [0.26–5.27]
Hormone receptors (HRs) 0.48
ER- and PR- 7 86 [63–100] 1
ER+ or PR+ 40 67 [52–86] 2.1 [0.06–3.72]
Histopathologic index 0.59
Grade 1–2 14 64 [35–100] 1
Grade 3 36 73 [59–91] 0.70 [0.39–5.19]
Systemic therapy 0.35
None 16 54 [33–86] 1
ChT 23 85 [70–100] 0.47 [0.15–1.49]
ChT + HT 14 43 [11–100] 0.48 [0.12–1.90]
Total RT doseb 0.27
≥ 60 Gy 43 76 [59–97] 1
< 60 Gy 13 50 [28–88] 1.8 [0.63–5.15]
NA = not applicable; CI = confidence interval; RR = relative risk for locoregional recurrence. aP values pertain to the relative risks. bTotal dose of 
radiotherapy to the tumor bed (whole breast dose + boost dose).Available online http://breast-cancer-research.com/content/11/4/R54
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To verify that these findings could be extrapolated, we com-
pared the characteristics of patients and tumors of the 53
patients included in this study with the 257 other patients
treated over the same period (1988 through 1999) at the Insti-
tut Curie who met the same inclusion criteria (age, medical his-
tory, therapeutic sequence) (Table 1). This comparison
showed that this RT-PCR series consisted of patients with
tumors with a more advanced clinical stage, higher histologic
grade, and more lymphovascular invasion and who therefore
more frequently received chemotherapy and a total dose to the
tumor bed higher than 60 Gy. All other patient, tumor, and
treatment characteristics were comparable. It could be
hypothesized that these differences were due, at the time of
this study (1988 to 1999), to technical parameters: tissue
samples for frozen storage would be easier to obtain from
larger tumors.
In this series of 53 patients, neither clinical nor pathologic fea-
tures were associated with increased locoregional recurrence
rates. Very young age, in particular, was not significantly asso-
ciated with increased locoregional recurrences, in contrast
with a previous study of unselected young patients from the
Institut Curie [6].
RNA expressions of 17 target genes were studied here with
RT-PCR for their association with locoregional control. They
are involved in hormone signaling, either directly (ERα, ERβ,
PR, NCoA3/AIB1, NCoR, GATA3,  CYP19/aromatase,
SKP2) or indirectly (HER family, IGF1-R) or in proliferation
(MKi67, cyclins E, and CAF-1). Classic hormone receptors
(ERα, PR) have been extensively explored in breast cancers
[10]. In contrast with previously published studies [25], a high
frequency of young women in this series had positive hormone
receptors (ERα and PR in 79% and 81% of cases with immu-
nohistochemistry, and in 75% and 82% of cases with RT-
PCR).
Among the genes activated in response to ER activation
(NCoA3/AIB1,  NCoR, SKP2, GATA3, CYP19/aromatase),
only the absence of CYP19/aromatase was significantly asso-
ciated with an increased locoregional recurrence rate (P =
0.003; relative risk = 0.49; 95% CI, 0.29 to 0.82). Given the
Table 3
Univariate and multivariate analyses of gene-expression prognostic factors (as continuous variables) for locoregional recurrences
Gene expression by quantitative rt-PCR (continuous variables) Univariate analysis Multivariate analysis
HR (RR)
[95% CI]
P HR (RR)
[95% CI]
P
Estrogen receptor-α 1.22 [0.90–1.66] 0.15
Estrogen receptor-β 0.61 [0.39–0.95] 0.04 0.54
Progesterone receptor 1.13 [0.88–1.45] 0.32
HER1 0.65 [0.37–1.13] 0.10 0.72
HER2 0.89 [0.64–1.25] 0.49
HER3 1.06 [0.55–2.02] 0.87
HER4 1.22 [0.91–1.63] 0.14
MKI 67 0.89 [0.61–1.30] 0.56
Cyclin E1 0.81 [0.48–1.36] 0.43
Cyclin E2 0.75 [0.49–1.14] 0.18
GATA 3 1.61 [0.95–2.73] 0.04 1.49 [0.92–2.39] 0.06
IGF1R 1.41 [0.93–2.14] 0.13
NCoR 0.90 [0.38–2.15] 0.82
NCoA3/AIB1 0.51 [0.21–1.22] 0.14
CYP19 (aromatase) 0.48 [0.28–0.80] 0.003 0.49 [0.29–0.82] 0.003
Skp2 0.52 [0.23–1.17] 0.10 0.18
CAF-1 p150 1.00 [0.48–2.12] 1.00
CAF-1 p60 1.00 [0.97–1.03] 0.94
RR = relative risk for locoregional recurrence calculated with the nonparametric Cox model; CI = confidence interval; HER = human epidermal 
receptor. Because of lack of prognostic values of the clinical variables in univariate analysis, none was entered in the multivariate analysis.Breast Cancer Research    Vol 11 No 4    Bollet et al.
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small size of this series, it also is noteworthy that the level of
GATA-3 was associated with a trend toward an increased
locoregional recurrence rate (P = 0.06; relative risk = 1.49;
95% CI, 0.02 to 2.39). CYP19/aromatase plays a critical role
in breast cancer development by converting androgen into
estrogens. CYP19/aromatase mRNA and protein have previ-
ously been detected in both tumor stroma and parenchymal
cells in breast cancer tissue [26]. Previous data demonstrated
that CYP19/aromatase mRNA is correlated with CYP19/aro-
matase enzymatic activity in cultured breast tumor fibroblasts
[27]. The importance of in situ estrogen production has been
demonstrated in breast carcinoma [28], where it is higher than
that in normal breast tissue [29,30]. Inhibition of the aromatase
pathway is considered to be clinically useful to reduce pro-
gression of breast tumors in postmenopausal women [31]. An
apparently paradoxic finding was that a low level of CYP19/
aromatase transcripts in this population of young, premeno-
pausal patients was significantly associated with an increased
locoregional recurrence rate. However, preclinical studies
demonstrated that estrogens or estrogenic compounds
repress the transcriptional control of CYP19/aromatase
[32,33]. It can be hypothesized that, in premenopausal
women, who already have high plasma estradiol levels, the
level of aromatase transcripts may be inversely correlated with
the plasma estradiol level [34]. Low tumor expression of
CYP19/aromatase  would reflect a high level of circulating
estrogen and would therefore be associated with poor out-
come. This finding is supported by a study by Zhang and col-
leagues [35] in a series of 162 invasive ductal breast
carcinomas that showed that aromatase mRNA levels were
lower in patients younger than 50 years, with tumors larger
than 2 cm and with axillary lymph node involvement [35].
However, the association between tumor aromatase expres-
sion and outcome remains controversial; no consistent corre-
lation between aromatase immunoreactivity, activity, or mRNA
level and known clinicopathologic factors or outcome has
been conclusively reported [35-40]. Some authors have even
reported, in univariate analysis, a correlation between high
tumor aromatase activity and poor outcome [37,40].
The association between tumor aromatase activity or expres-
sion and estrogen receptors is also very controversial, as
some authors have reported a positive correlation [35,36,40],
whereas others have reported no correlation [37], or even an
inverse correlation [39]. In the present series, no correlation
was observed between aromatase expression and either age,
hormone receptors, or histologic grade (data not shown).
GATA3 is a transcription factor involved in human growth and
differentiation. Gene-expression profiling has shown that
GATA3 is highly expressed in luminal A and B subtypes of
cancer and closely related to ERα [41-43]. This study, the first
to our knowledge to use quantitative RT-PCR in a population
of young patients, showed a trend toward an association
between a high level of GATA3 expression and higher locore-
gional recurrence rates. The favorable outcome in very young
patients with ER-positive breast cancers is a controversial
issue. Aebi and associates [44] reported a series of 3,500
premenopausal women treated in four randomized trials from
the International Breast Cancer Study Group (IBCSG). They
found that younger patients with ER-positive tumors had a sig-
nificantly poorer disease-free survival than did younger
patients with ER-negative tumors.
In addition, conflicting data have been published regarding the
independent prognostic value of GATA3 in unselected breast
cancer. Some studies found GATA3 to be associated with
good prognosis [45,46]. The study by Voduc and colleagues
[47] found no independent prognostic value of GATA3  in
3,119 breast cancer patients with immunohistochemistry on
tissue microarrays.
ERβ expression in breast (normal and tumor) and the relation
between ERβ and other clinicopathologic features and its role
in hormone therapy have been extensively investigated
(recently reviewed by Zhao and others [48]). A consensus
seems to have been reached regarding the protective role of
ERβ  against breast cancer development. No clinically vali-
dated cut-off has been defined for ERβ ; transcript levels are
generally lower in tumor tissue than in normal tissue. The loss
of  ERβ  expression by promoter methylation, frequently
observed in breast tumors, has led to the hypothesis that ERβ
is a possible tumor-suppressor gene [49]. The ERβ transcript
level in breast cancers was analyzed in a recent study by
Anders and colleagues [50]. With clinically annotated micro-
array data from 200 early-stage breast cancers in women, they
observed that the ERβ transcript level was statistically lower in
young women (younger than 45 years) than in older women
(older than 65 years; P = 0.02). As expected from these data,
the present study confirmed the protective effect of ERβ in
terms of locoregional control.
In younger women with breast cancer, a higher incidence of
growth-factor receptors, namely HER2, was observed both in
terms of protein expression, associated with a more-aggres-
sive phenotype [51,52], and of HER2 gene expression with no
predictive value for DFS [50].
Interestingly, the HER family and IGF1R have been shown to
be intertwined with the estrogen-mediated signaling pathway
[53].
Hormone receptors and growth-factor receptors act as
mitogens, promoting cell proliferation in normal tissue and in
breast carcinomas. Strong evidence suggests that IGF1,
HER, and estrogen-mediated signaling are closely connected
[54]. HER1 (or EGFR) has been described as both a prognos-
tic marker and a predictor of hormone-therapy resistance in
breast cancer [55]. However, downregulation of EGFR hasAvailable online http://breast-cancer-research.com/content/11/4/R54
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never been explored. The present study showed a trend
toward an impact of low EGFR expression on locoregional
recurrence in young women. No other effect was observed for
any of the other growth-factor receptors.
Proliferation markers, included in the definition of histologic
grading [14], are also prognostic factors associated with poor
outcome, high locoregional recurrence rates [5,56], and pre-
dictive factors of the response to chemotherapy [15,57]. The
levels of gene expression of two subunits of CAF-1 (p150 and
p60) [58] and other proliferation markers (the classic KI67,
cyclins E1 and E2, and SKP2) were well correlated in the
present study (data not shown) but were not associated with
a higher risk of locoregional recurrence. One explanation
could be a lack of statistical power, as most patients (68%) in
this series had grade 3 tumors.
The search for a signature associated with local recurrence for
premenopausal women treated with breast-conserving thera-
pies by using high-throughput gene-expression analyses is
ongoing [23,24,59]. The fact that gene-expression levels of
neither CYP19/aromatase nor GATA3 were found to be asso-
ciated with risk of local recurrences in the two studies [23,24]
that gave information about the patients' age could reflect
either the lower sensitivity of microarray data compared with
RT-PCR or a difference in the studied populations. Correla-
tions between quantitative RT-PCR measures and microarray
data have been deceiving. Koscielny and associates [60]
investigated the correlation between gene expressions evalu-
ated by the qRT-PCR and microarrays in 42 colon tumors. Of
39 genes randomly selected for analysis by qRT-PCR, seven
showed a correlation between microarrays and quantitative
RT-PCR of 0.5 or less. The authors concluded that microarray
and qRT-PCR data are not deterministically related and there-
fore not interchangeable.
Conclusions
The present results highlight the role of estrogen-signaling
pathways, mainly CYP19/aromatase, GATA3, and ERβ, in the
risk of recurrence in young women with breast cancer. These
preliminary results must be confirmed in a larger prospective
study. One hypothesis would be that the higher the level of cir-
culatory estrogen, the higher the risk of locoregional recur-
rence, whereas low tumor expression of aromatase and high
tumor expression of GATA3 would reflect only the high plasma
estrogen levels. However, recent data also give credit to the
fact that breast cancer arising in young women is a distinct
biologic entity driven by specific oncogenic pathways [50,61].
In conclusion, our results demonstrate that the hormone status
is of extreme importance for the prognosis of premenopausal
breast cancer patients. Although these findings must be con-
firmed in a larger prospective study on patients younger than
40 years, assessing the expression levels of hormone-related
genes, among which aromatase, might contribute to predict
disease outcome in young breast cancer patients.
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